News

Asarina Pharma AB (publ) Q2 Report 2021 released

Asarina Pharma CEO Peter Nordkild: “Q2 2021 was a difficult quarter for us and our shareholders. It was also a definitively transformative one. The failure of our Phase IIa study in Menstrual Migraine coincided with the approval of our CTA in Tourette syndrome by the Danish Medicines Agency, and the granting of our first US…

Full PDF

Asarina Pharma reports topline results in Phase IIa Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today releases topline results from its Phase IIa study of Sepranolone for the treatment of menstrual migraine. While a 25% reduction in menstrual migraine days was achieved across the patient population, a statistically significant difference compared to placebo was not obtained for the study’s primary and secondary endpoints.…

Full PDF

Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling

(Stockholm, 8 June 2021.) The US Patent and Trademark Office has granted a patent for Sepranolone for the treatment of Tourette, Obsessive-Compulsive Disorder (OCD) and pathological gambling. CEO Peter Nordkild: “The powerful neurosteroid Allopregnanolone (ALLO) seems to be the missing link in a raft of stress-related disorders, from Tourette to OCD, characterized by tics and…

Full PDF

Asarina Pharma obtains convertible loan for continued research on neurological conditions including Obsessive Compulsive Disorder

(Stockholm, 31 May 2021) Asarina Pharma AB (publ) has obtained a convertible loan of 5.3 MSEK from Östersjöstiftelsen (ÖSS), one of its key shareholders, for ongoing and upcoming R&D into neurological disorders including OCD (Obsessive Compulsive Disorder).

Full PDF

Asarina Pharma: Issuance of 700,000 warrants completed

Stockholm, 28 May 2021: Asarina Pharma AB (publ) today announces that it has issued 700,000 new warrants which have all been acquired by the management and other members of the Asarina staff.

Full PDF